Protagonist Therapeutics, Inc. (PTGX) has a negative trailing P/E of -50.4, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 32.4 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -1.99%, forward earnings yield 3.09%. PEG 3.41.
Criteria proven by this page:
Overall SharesGrow Score: 67/100 with 4/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -3.8 | -0.03 | -2.21 | 0.00 | - |
| 2017 | -10.0 | 0.16 | -3.62 | 18.34 | - |
| 2018 | -3.9 | 0.23 | -1.07 | 4.87 | - |
| 2019 | -2.4 | -0.03 | 2.28 | 790.27 | - |
| 2020 | -10.5 | 0.29 | 2.48 | 24.22 | - |
| 2021 | -12.6 | -0.33 | 5.28 | 57.91 | - |
| 2022 | -4.2 | 0.86 | 2.48 | 20.13 | - |
| 2023 | -16.5 | 0.37 | 3.87 | 21.69 | - |
| 2024 | 8.6 | -0.02 | 3.52 | 5.47 | - |
| 2025 | -42.7 | 0.29 | 9.03 | 120.66 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-5.72 | $0.00 | $-37.18M | - |
| 2017 | $-2.09 | $20.06M | $-36.96M | -184.2% |
| 2018 | $-1.74 | $30.93M | $-38.92M | -125.9% |
| 2019 | $-2.98 | $231K | $-77.19M | -33414.3% |
| 2020 | $-1.92 | $28.63M | $-66.15M | -231.1% |
| 2021 | $-2.65 | $27.36M | $-122.63M | -448.2% |
| 2022 | $-2.52 | $26.58M | $-123.41M | -464.3% |
| 2023 | $-1.39 | $60M | $-78.96M | -131.6% |
| 2024 | $4.23 | $434.43M | $275.19M | 63.3% |
| 2025 | $-2.05 | $46.02M | $-130.15M | -282.8% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $3.23 | $-9.28 – $14.86 | $441.4M | $31.46M – $717.21M | 8 |
| 2027 | $-0.68 | $-1.13 – $-0.09 | $155.59M | $85.83M – $304.98M | 7 |
| 2028 | $1.56 | $-7.56 – $10.54 | $303.31M | $39.08M – $524.47M | 6 |
| 2029 | $2.57 | $-0.34 – $5.00 | $419.23M | $54.01M – $724.91M | 4 |
| 2030 | $4.65 | $-0.62 – $9.05 | $601.88M | $77.54M – $1.04B | 2 |
